Free Trial

This company recently went public with an IPO on Tuesday, August 26th 2025. They issued 2,000,000 shares at $4.00 - $6.00 per share. We will continue to update data for CURX as it becomes available.

Curanex Pharmaceuticals (CURX) Competitors

$5.60 +0.41 (+7.90%)
As of 04:00 PM Eastern

CURX vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Curanex Pharmaceuticals stock or one of its competitors? The main competitors of Curanex Pharmaceuticals include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Curanex Pharmaceuticals vs. Its Competitors

Curanex Pharmaceuticals (NASDAQ:CURX) and 180 Life Sciences (NASDAQ:ATNFW) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/AN/AN/AN/A
180 Life SciencesN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A N/A N/A
180 Life Sciences N/A N/A N/A

7.9% of Curanex Pharmaceuticals shares are held by institutional investors. 1.5% of Curanex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Curanex Pharmaceuticals had 5 more articles in the media than 180 Life Sciences. MarketBeat recorded 6 mentions for Curanex Pharmaceuticals and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.88 beat Curanex Pharmaceuticals' score of 0.16 indicating that 180 Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Curanex Pharmaceuticals Neutral
180 Life Sciences Very Positive

Summary

Curanex Pharmaceuticals beats 180 Life Sciences on 3 of the 4 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CURX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CURX vs. The Competition

MetricCuranex PharmaceuticalsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market CapN/A$844.58M$2.57B$9.75B
Dividend YieldN/A4.84%2.54%4.02%
P/E RatioN/A1.1221.9126.39
Price / SalesN/A26.5894.11159.28
Price / CashN/A19.5623.4359.42
Price / BookN/A6.7233.486.59
Net IncomeN/A-$4.49M$26.72M$265.83M
7 Day PerformanceN/A1.86%0.73%0.18%
1 Month PerformanceN/A4.71%2.16%2.13%
1 Year PerformanceN/A22.55%26.10%21.07%

Curanex Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CURX
Curanex Pharmaceuticals
N/A$5.60
+7.9%
N/AN/A$0.00N/A0.00N/ANews Coverage
ATNFW
180 Life Sciences
N/A$0.27
+24.8%
N/A+2,713.9%$0.00N/A0.007Positive News
Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.24
-40.2%
N/AN/A$0.00$110.87K0.0040Gap Down
ALVOW
Alvotech
N/A$1.23
+5.3%
N/A-55.5%$0.00$560.10M0.004Positive News
Gap Down
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.03
+6.5%
N/A+139.5%$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.14
+42.6%
N/AN/A$0.00$39.19M0.0070Positive News
Gap Up
BTMDW
biote
N/A$0.01
-10.6%
N/A-95.8%$0.00$199.07M0.00N/AGap Down
BCTXW
BriaCell Therapeutics
N/A$0.02
+8.9%
N/A-94.3%$0.00N/A0.008Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:CURX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners